3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
42
Lymphoma, Non-Hodgkin
12
Lymphoma, B-Cell
12
Lymphoma, Follicular
7
Lymphoma
7
Recurrence
5
Lymphoma, Mantle-Cell
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Lymphoma, B-Cell, Marginal Zone
3
Hodgkin Disease
2
Dendritic Cell Sarcoma, Interdigitating
2
Burkitt Lymphoma
2
Neoplasms
1
Leukemia, Hairy Cell
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
87
fludarabine
74
Tacrolimus
45
fludarabine phosphate
44
Mycophenolic Acid
42
Whole-Body Irradiation
41
Busulfan
35
Melphalan
31
Antilymphocyte Serum
24
thymoglobulin
22
Methotrexate
22
Rituximab
21
venetoclax
20
Standard of Care
20
Sirolimus
20
Azacitidine
20
Thiotepa
19
Stem Cell Transplantation
18
Granulocyte Colony-Stimulating Factor
18
Practice Guidelines as Topic
16
Cytarabine
16
Nivolumab
15
Filgrastim
15
Dexamethasone
14
Cyclosporine
13
Bortezomib
13
Mesna
12
Peripheral Blood Stem Cell Transplantation
11
trametinib
10
Specimen Handling
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hematologic Neoplasms
×
polatuzumab vedotin
×
Clear all
NCT04844866
2026-04-29
DALY 2-EU
Miltenyi Biomedicine GmbH
Phase 2
Recruiting
213 enrolled